Physician profile
Toni L Brent
NPI 1821379561
$15,619.13
in general payments reported to CMS, 2019-2025
11 companies · $6,963 in 2025
The $6,963 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,431 · 2022: $1,895 · 2023: $309 · 2024: $1,021 · 2025: $6,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,188 · Food and Beverage: $2,593 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,275 · Travel and Lodging: $1,225 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,187.50 |
| Food and Beverage | $2,592.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,275.00 |
| Travel and Lodging | $1,225.45 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,288.84 | 2021-2025 | Caplyta |
| Alkermes, INC. | $6,410.34 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $484.78 | 2021-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $381.00 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $266.55 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $254.11 | 2021-2022 | |
| Axsome Therapeutics, INC. | $124.98 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $119.31 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $111.51 | 2023 | Qelbree |
| Johnson & Johnson Health Care Systems INC. | $105.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $72.71 | 2021-2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Brent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.